Skip to Content
End of Year Sale. Save up to twenty-five percent off sitewide.End of Year Sale. Save up to twenty-five percent off sitewide.

Rheumatic immune-related adverse events, An Issue of Rheumatic Disease Clinics of North America, 1st Edition

Authors :
Alexa Simon Meara & David Liew
Date of Publication: 05/2024
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease ...view more
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs: current approaches to management; and more.
Add to Cart
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs: current approaches to management; and more.

Key Features
  • Contains 15 relevant, practice-oriented topics including myositis irAEs; sicca symptom irAEs; de novo connective tissue disorders as irAEs; imaging in rheumatic irAEs; combining biologic DMARDs with immune checkpoint inhibitors; the impact of DMARDs and glucocorticoids on cancer response to immune checkpoint inhibitors; and more.
  • Provides in-depth clinical reviews on rheumatic immune-related adverse events, offering actionable insights for clinical practice.
  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Author Information
Edited by Alexa Simon Meara, MD, Associate Professor, Division of Oncology, Division Rheumatology and Immunology, The Ohio State Wexner Medical Center, USA and David Liew, MD, Consultant Rheumatologist and Clinical Pharmacologist Project Lead, Medicines Optimisation Service, Department of Clinical Pharmacology and Therapeutics, Austin Hospital, Heidelberg, VIC, Australia